Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Rating of “Hold” by Analysts

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has earned a consensus rating of “Hold” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $4.94.

Several equities analysts have recently weighed in on IRWD shares. Zacks Research raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a report on Wednesday, October 8th.

Ironwood Pharmaceuticals Price Performance

NASDAQ:IRWD opened at $1.63 on Tuesday. The firm has a market cap of $264.77 million, a price-to-earnings ratio of -32.59 and a beta of 0.30. The company has a 50 day moving average price of $1.38 and a 200-day moving average price of $0.98. Ironwood Pharmaceuticals has a 1-year low of $0.53 and a 1-year high of $5.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.16. The firm had revenue of $85.24 million during the quarter, compared to analyst estimates of $62.02 million. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in IRWD. McAdam LLC acquired a new stake in Ironwood Pharmaceuticals during the 1st quarter worth $40,000. OVERSEA CHINESE BANKING Corp Ltd acquired a new position in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at about $25,000. SG Americas Securities LLC acquired a new position in shares of Ironwood Pharmaceuticals during the 3rd quarter valued at about $48,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Ironwood Pharmaceuticals during the 1st quarter valued at about $57,000. Finally, R Squared Ltd boosted its position in shares of Ironwood Pharmaceuticals by 286.5% during the 2nd quarter. R Squared Ltd now owns 38,765 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 28,735 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.